{"id":2929,"date":"2016-11-03T16:47:11","date_gmt":"2016-11-03T16:47:11","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=18164"},"modified":"2016-11-03T16:47:11","modified_gmt":"2016-11-03T16:47:11","slug":"medical-marijuana-inc-investment-axim-biotechnologies-inc-publishes-product-pipeline-chart-pharma-clinical-trials-program-cannabinoid-rd","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2016\/11\/03\/medical-marijuana-inc-investment-axim-biotechnologies-inc-publishes-product-pipeline-chart-pharma-clinical-trials-program-cannabinoid-rd\/","title":{"rendered":"MEDICAL MARIJUANA, INC. INVESTMENT AXIM\u00ae BIOTECHNOLOGIES, INC. PUBLISHES PRODUCT PIPELINE CHART FOR PHARMA CLINICAL TRIALS PROGRAM IN CANNABINOID R&D"},"content":{"rendered":"

Cannabinoid Innovator\u2019s Product Pipeline Highlights Timelines of Its Intellectual Property (IP) Protected Cannabinoid-Based Products from Pre-Clinical to NDA for Multiple Indications \u00a0<\/span><\/em>\u00a0<\/b><\/h3>\n

NEW YORK \u2013 Nov. 3, 2016 \u2013 <\/b>Medical Marijuana, Inc.<\/span> (OTC: MJNA) today announced that its investment <\/span>AXIM<\/span>\u00ae<\/span> Biotechnologies, Inc. (AXIM<\/span>\u00ae<\/span> Biotech<\/span><\/a>) (OTC: AXIM), a world leader in cannabinoid research and development, has published a <\/span>product pipeline chart<\/span><\/a> on its website that highlights the timelines from pre-clinical to a new drug application (NDA) for its numerous intellectual property-protected cannabinoid-based products. <\/span><\/p>\n

The Company\u2019s <\/span>product pipeline chart<\/span><\/a> shows what stage of clinical trials each drug of AXIM\u00ae Biotech is in, the indication the drug is intended to treat and the expected date to receive an NDA from the U.S. Food and Drug Administration (FDA) and\/ or European Medicines Agency (EMA). The chart also shows the anticipated market introduction date of the Company\u2019s various functional food and nutraceutical products. <\/span><\/p>\n

\u201cWe commend AXIM for publishing a product pipeline chart on its website as it provides potential patients and investors with critical Company information about the numerous cannabinoid-based therapeutic products that AXIM currently has undergoing clinical trials and when those products are anticipated to be on the market and approved by the FDA and EMA,\u201d said Medical Marijuana, Inc. Chief Executive Officer Dr. Stuart Titus. \u201cIt\u2019s exciting to see the actual timelines for these cannabinoid-based innovations currently in development, as we\u2019re confident that once on the market these novel therapeutics will provide consumers with a wide variety of new options worldwide.\u201d<\/span><\/p>\n

View the product pipeline chart <\/span>here.<\/span><\/a><\/p>\n

An AXIM<\/span>\u00ae<\/span> Biotech breakthrough invention on pace to be fully registered by the EMA and FDA by the end of 2018 is the world\u2019s first patented cannabinoid controlled-release chewing gum: MedChew Rx\u2122. Recently featured by <\/span>Reuters<\/span><\/a> global news agency, MedChew Rx\u2122 will change the way that medicine is delivered to patients worldwide. Directly compared to a sublingually delivered cannabis-based product currently on the market for multiple sclerosis (MS) in the <\/span>Reuters<\/span><\/a> article, the potential economic impact for MedChew Rx\u2122 is estimated at $4.8 billion USD \u2013 for spasticity and pain associated with MS.<\/span><\/p>\n

AXIM\u2019s pipeline of intellectual property (IP) protected cannabinoid-based products include:<\/span><\/p>\n